EN | ES | DE | FR | IT | 日本語 | 한국어 | 中文

Buyer Beware: Secret Sales May Result in Subsequent Patent Invalidity

Final Decision Reached in Initial Insulin IPR Proceeding
January 18, 2019
CAFC Rules USPTO Exceeded Its Authority Adjusting Patent Term
February 5, 2019
Show all

Patent Icon

Buyer Beware: Secret Sales May Result in Subsequent Patent Invalidity

 

By: Katie Rubino

 


Recently on January 22, 2019, the Supreme Court affirmed the Federal Circuit’s judgment in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA Inc. The case centered around the “on sale” bar of the Leahy-Smith America Invents Act (AIA), effective as of March 16th, 2013. Under the AIA, 35U.S.C. ⸹102(a)(1) bars an inventor from a receiving a patent on an invention that was “in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.” The case posed the question of whether an inventor’s sale of an invention to a third party that is obligated to keep the invention confidential qualifies as prior art for the purpose of determining patentability?

The case first developed when Helsinn Healthcare S.A. (Helsinn) starting making a treatment for chemotherapy induced nausea and vomiting using the chemical palnosetron. Palnosetron is a 5-HT3 antagonist, given either orally or intravenously prior to chemotherapy to prevent delayed nausea and vomiting. Palnosetron is a favorable product due to its long half life (between 40-50 hours), enabling long periods of time between subsequent doses. While developing this product, in 2001, Helsinn entered into an agreement with another company granting that company the right to distribute, promote, market, and sell palnosetron in the 0.25mg dosage form. The agreement specified that the company would keep proprietary information secret.

Two years later in 2003, Helsinn filed a provisional patent application for the 0.25mg dosage form. Over the next ten years, Helsinn continued to file patent applications, including one filed in 2013, after enactment of the AIA.  In 2011, Teva Pharamceuticals USA Inc (Teva) sought approval to market a generic 0.25mg palonsetron product. At this point, Helsinn sued Teva for patent infringement of its patents covering palonsetron. Teva then countered that Helsinn’s patent filed in 2013 was invalid under the “on sale” provision of the AIA. Teva claimed that the 0.25mg dose was on sale more than one year before Helsinn filed its original provisional patent application in 2003.

The District Court held that the AIA’s on sale bar did not apply because the agreement between Helsinn and the other company, even if considered a public disclosure, did not disclose the 0.25mg dose. The Federal Circuit reversed, holding that the sale was publicly disclosed, regardless of whether the details of the invention were publicly disclosed in the terms of the sale agreements. The Supreme Court then heard the case, and in a 9-0 ruling, affirmed the decision of the Federal Court. The Supreme Court ruled that a commercial sale to a third party who is required to keep the invention confidential may place the invention “on sale” under ⸹102(a). The Supreme Court reasoned that a sale or offer of sale need not make an invention available to the public to constitute invalidating prior art. The Supreme Court further reasoned that “secret sales” could indeed invalidate a patent.

This case is monumental, in that even though it did not eliminate secret prior art, it provides clarity as to the scope of the “on sale” bar, and allows inventors and lawyers alike to create custom patent strategies based on this confirmed ruling. Going forward, this case offers several key takeaways. First, this decision will particularly impact small companies looking to partner with larger corporations to bring their novelty to market. This is especially true of biotech and pharma start-ups, that often collaborate with bigger corporations to offset costs needed for drug discovery and research and development. Secondly, inventions must now be evaluated early on to determine whether they should maintain a trade secret or be protected via patents. Further, inventions deemed patentable should be considered for early provisional patent applications filings before any anticipated disclosures or offers for sale. Lastly, confidentiality agreements such as non-disclosure agreements (NDA) should not be relied upon to prevent loss of patent rights based on offers for sale of the invention. Instead, patent rights need to be aggressively pursued and monitored.  Working in conjunction with counsel to create an IP strategy that  will have meaning and value for many years to come is paramount.

Ask a Question


Leave a Reply

Your email address will not be published. Required fields are marked *